NASDAQ$ICUI

ICU Medical Inc. · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

ICU Medical's first quarter results reflected revenue decrease and net income decline compared to the same period last year, but were generally in line with expectations except for additional demand within IV Solutions business due to the COVID-19 pandemic.

ICU Medical reported first quarter 2020 revenue of $328.6 million, a decrease compared to $330.9 million in the same period last year. GAAP net income was $16.8 million, or $0.78 per diluted share, compared to $31.0 million, or $1.44 per diluted share, for the first quarter of 2019. Adjusted diluted earnings per share were $1.81, compared to $2.58 for the first quarter of 2019. Adjusted EBITDA was $63.0 million, compared to $77.9 million for the first quarter of 2019.

  • First quarter revenue was $328.6 million, compared to $330.9 million in the same period last year.
  • GAAP gross profit was $121.4 million, compared to $135.3 million in the same period last year.
  • GAAP net income was $16.8 million, or $0.78 per diluted share, compared to $31.0 million, or $1.44 per diluted share, for the first quarter of 2019.
  • Adjusted diluted earnings per share were $1.81 as compared to $2.58 for the first quarter of 2019.

Headline financials

Total Revenue

$329M

Previous: $331M-0.7%
EPS (adj)

$1.81

Previous: $2.58-29.8%
Adjusted EBITDA

$63M

Previous: $77.9M-19.2%
GAAP Gross Margin

37.0%

Previous: 41.0%-9.8%
Capital Expenditures

-$25.5M

Previous: -$28.7M+11.2%
Free Cash Flow

-$8.63M

Previous: $2.33M-470.8%
Net Income

$16.8M

Previous: $31M-45.7%
Operating Income

$26.1M

Previous: $30.4M-14.2%
Gross Profit

$121M

Previous: $135M-10.3%
Cash & Equivalents

$420M

Previous: $292M+43.7%
Total Assets

$1.82B

Previous: $1.61B+12.6%
Stock-Based Comp

$6.94M

Previous: $6.21M+11.8%

Revenue & EPS history

ICU Medical · Revenue · Quarterly

$329M

Q1 2020-0.7%vs Q1 2019
Beat estimate in 14 of 16 quarters(88%)
ActualEstimate

Revenue by segment

ICU Medical · $212M total across 2 segments · Q1 2020

  • Consumables
    $124M+2.5%
  • Infusion Systems
    $88.4M+4.9%

Forward guidance

The Company is revising adjusted EBITDA from a range of $240 million to $260 million to a range of $230 million to $250 million and adjusted earnings per share from a range of $6.50 to $7.20 to a range of $5.95 to $6.65.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

+0.3%

Avg return

Earnings day

-1.1%

Avg return

5 days after

-0.3%

Avg return

30 days after

52%

38 / 73 earnings

Positive

+22.4%

Q2 2024

Best reaction

-33.3%

Q2 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.8%-0.8%+10.7%
Q4 2025+4.8%+3.6%-16.3%
Q3 2025+8.2%+7.3%+9.9%
Q1 2025-3.3%-4.9%-6.9%
Q4 2024-2.3%-4.1%-6.4%
Q3 2024-1.9%-5.8%-7.1%
Q2 2024+22.4%+19.7%+31.2%
Q1 2024-0.1%+6.3%+7.6%
Q4 2023+6.5%-0.2%+1.6%
Q3 2023-17.8%-20.2%-15.9%
Q2 2023-15.2%-15.6%-16.8%
Q1 2023+13.3%+8.7%+3.9%
Q4 2022-3.6%-4.2%-7.3%
Q3 2022+6.7%+21.4%+11.8%
Q2 2022-7.4%-4.7%-8.0%
Q1 2022-10.4%-15.0%-14.9%
Q4 2021+5.8%+9.0%+4.3%
Q3 2021+2.1%+2.7%-6.4%
Q2 2021+0.7%+1.2%+6.1%
Q1 2021-5.0%-6.5%-2.1%
Q4 2020-5.5%-6.8%-4.4%
Q3 2020+0.6%+4.8%+5.6%
Q2 2020+8.8%+5.0%+9.8%
Q1 2020-8.8%-13.7%-8.0%
Q4 2019-4.2%-4.8%-8.2%
Q3 2019+6.9%+4.3%+6.8%
Q2 2019-33.3%-31.2%-36.6%
Q1 2019-2.7%-3.3%-2.2%
Q4 2018+2.5%-4.9%-2.8%
Q3 2018-10.6%-14.8%-10.6%
Q2 2018+2.2%+2.4%+3.7%
Q1 2018+1.4%+4.3%+12.4%
Q4 2017+4.6%+7.5%+9.1%
Q3 2017+8.6%+10.1%+11.7%
Q2 2017-2.9%-2.4%+3.4%
Q1 2017-0.2%-0.1%+6.2%
Q4 2016+0.7%-1.0%+1.5%
Q3 2016-0.4%-0.9%+2.5%
Q2 2016+7.5%+6.1%+8.6%
Q1 2016-1.0%
Q4 2015-8.7%
Q3 2015+5.8%
Q2 2015+19.9%
Q1 2015+7.3%
Q4 2014+2.2%
Q3 2014+13.6%
Q2 2014+10.5%
Q1 2014+3.3%
Q4 2013+0.1%
Q3 2013+3.0%
Q2 2013-6.7%
Q1 2013+1.3%
Q4 2012+1.1%
Q3 2012+3.7%
Q2 2012-0.2%
Q1 2012+0.8%
Q4 2011+1.9%
Q3 2011+0.2%
Q2 2011-3.9%
Q1 2011+2.2%
Q4 2010+0.1%
Q3 2010-0.9%
Q2 2010+3.4%
Q1 2010-1.0%
Q4 2007-1.0%
Q4 2009-1.0%
Q3 2009-0.8%
Q3 2008-0.8%
Q2 2009-0.6%
Q2 2008-3.9%
Q1 2009-3.9%
Q4 2008-3.9%
Q1 2008-3.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro